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Abstract
Background: Little is known about the ICD performance using enhanced detection algorithms in unselected, non-
trial patients. Performance of recent generation ICD equipped with SmartShock™ technology (SST) for detection
and conversion of ventricular tachyarrhythmias (VTA) was investigated.
Methods: 4P was a prospective, multicenter, observational study conducted in 10 Swiss implanting centers.
Patients with a Class I indication according to international guidelines were included and received an ICD with SST.
ICD discrimination capability was assessed by evaluating SST performance; therapy efficacy was assessed by rate of
VTA conversions by ATP and by rescue shocks.
Results: Overall, 196 patients were included in the analysis with a mean duration of follow-up of 27.7 months (452
patient-years of observation). Patient-specific rather than recommended programming was preferred. Device-
detected episodes were frequent (5147 episodes in 146 patients, 74.5%). In 44 patients (22.4%), 1274 episodes were
categorized as VTA; only 215 episodes were symptomatic. ATP was the first-line therapy and highly effective (99.9%
success rate at the episode level, 100.0% at the patient level). Rescue shocks were rare (66 episodes in 28 patients);
7 shocks in 5 patients (2.6%) were inappropriate. Death and hospitalization rates were low.
Conclusions: In a cohort of non-trial, unselected ICD patients, VTA episodes were frequent. The 4P results confirm the
robustness of VTA detection by SST and the effectiveness of ATP treatment, hence limiting overall ICD shock burden.
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Background
Implantable cardioverter defibrillator (ICD) therapy is the
mainstay for the primary and secondary prevention of
arrhythmic sudden death by treating ventricular tachyar-
rhythmias (VTA) in three programmable rate zones:
ventricular tachycardia (VT), fast ventricular tachycardia
(FVT), and ventricular fibrillation (VF) [1]. The indica-
tions for ICD implantation are based on solid results from
many randomized controlled endpoint trials in carefully
selected patient populations. However, in daily practice,
patients may differ substantially from those included in
pivotal trials. This raises the question of whether the bene-
fits seen in a controlled trial would also apply under the
more heterogeneous conditions of daily practice in terms
of such clinical outcomes as hospitalizations, mortality,
and clinically symptomatic events.
By far, the leading cause of inappropriate therapy is
the misclassification of supraventricular tachycardia
(SVT), most commonly atrial fibrillation with high ven-
tricular rates. Other causes include intracardiac (T-wave)
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oversensing, extra-cardiac (lead) noise, and non-sustained
or self-terminating VT/VF [2, 3]. As a consequence,
evidence-based shock reduction strategies based on en-
hanced detection algorithms, such as SmartShock™ tech-
nology (SST), have been developed and investigated in
well-designed clinical trials [4].
Latest generation ICDs are antitachycardia-pacing
(ATP) devices with defibrillation backup [5, 6]. Ultimately,
better discrimination has led to improved ATP efficacy
thus reducing overall ICD shocks and their deleterious
effects [7–9].
The aim of the Prospective Study on Predictive Quality
with Preferencing PainFree ATP therapies (4P) was to
generate real-world evidence on technical and clinical out-
comes of detected, categorized and treated arrhythmic
episodes occurring in patients who received an ICD with
SST enhanced detection algorithms.
Methods
Study design
The Prospective Study on Predictive Quality with Prefer-
encing PainFree ATP therapies (4P) was a prospective,
multicenter, observational study of planned 24months
duration aimed at generating real-world evidence of ven-
tricular tachyarrhythmia management by implantable
cardioverter defibrillators (ICD) under conditions of
daily practice. The study is registered on clinicaltrials.gov
with the reference number NCT01509378.
Study population
Eligible patients were adults who gave their written in-
formed consent for participation in the study and implant-
ation of an ICD based on a Class I indication for primary
or secondary prevention of sudden cardiac death accord-
ing to the latest published guidelines [10, 11]. Single-
chamber (SC), dual-chamber (DC) and triple-chamber
(CRT-D) devices, either as new implants, upgrades or
replacements, were included.
Leads could be from any manufacturer. A connection
to the CareLink™ network was required. Patients with
permanent atrial fibrillation, a life expectancy of less
than 24months due to another non-cardiac disease or
participating in another concomitant trial were excluded.
The study was conducted in accordance with the Declar-
ation of Helsinki. Ethical Review Board approval was
obtained prior to study start from the corresponding
institutions of all participating centers.
Study outcomes of interest
The primary objective of the study was to document device
activity and performance in patients with a Class I indica-
tion seen in daily practice. In order to assess SST capability
to detect and categorize device-based episodes, sensitivity,
specificity, positive- and negative predictive values were
computed based on the number device-detected, discrimi-
nated and categorized VTAs, ATP therapies, and rescue
shocks. Computation of episodes considered both number
of episodes and number of patients having experienced one
or more of such episodes during the follow-up period. The
secondary objective was to report medical outcomes in
these patients: adjudicated symptomatic events; hospitaliza-
tions (all-cause, cardiac, and arrhythmia-related), deaths
(all-cause, cardiac), and severe adverse events including ser-
ious adverse device effects (SADE). Finally, in addition to
symptoms registered at any of the follow-up visits, patients
were encouraged to consult or to inform the follow-up
center if they had symptoms suggestive of arrhythmia epi-
sodes such as syncope, pre-syncope, palpitations or shock.
An expert board of two experienced investigators and one
external expert, not involved in the trial, analyzed these
events. Symptomatic events were adjudicated and classified
as VTA or not by the expert board, using the device-
recorded data.
Device features and programming
All implanted ICD devices featured enhanced detection
algorithms integrated in the SST (Medtronic Inc., Min-
neapolis, MN, USA) package, which includes: Lead Noise
Discrimination differentiates RV lead noise from VT/VF
by comparing a far-field EGM signal to near-field sens-
ing; RV Lead Integrity Alert extends the VF detection
time, triggers programmable alerts and increases diag-
nostic data collection and monitoring in case of lead
malfunction; PR-Logic and Wavelet are algorithms that
differentiate ventricular from supraventricular rhythms
considering either the relation between A and V EGMs,
for PR-logic, or morphology of the V EGM during tachy-
cardia compared to V EGM during sinus rhythm; T-
wave oversensing withholds therapy if there is evidence
that a fast ventricular rate results from double-counting
due to T-wave oversensing; Confirmation + confirms the
presence of an arrhythmia by comparing the rhythm
cycle length to a calculated confirmation interval before
a shock is delivered following the capacitor charge.
All participating centers received a recommendation for
ICD programming strategies based on available evidence.
Such evidence-based programming was recommended for
all patients. In brief, in primary prevention, recommended
cycle length for VF detection was 320ms with an initial
Number of Intervals to Detect (NID) of 30/40 [12]. In
addition, FVT and VT detection was to be set OFF. The
VT monitoring zone was based on a cycle length of 400ms
and a NID of 32 [12]. All SST algorithms were to be
switched ON with SVT limit set at 260ms [13–15]. In
secondary prevention, the same settings applied except the
recommended cycle length for VF detection was 300ms
with initial NID 30/40 [16] and VT detection switched ON
with a cycle length of 360ms with an initial NID of 16.
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Primary therapy was ATP [11]. These programming set-
tings are based on published scientific evidence [11, 13–16]
and were recommended as such in the study protocol. Ac-
cordingly, specific programming information was handed
out to each implanter as part of the study documentation
before trial initiation (Figs. 5 and 6 in Appendix). The
protocol allowed divergences based on the judgment of the
implanting or follow-up physician.
Statistical analysis
All patients who matched with the inclusion and exclusion
criteria were included in the statistical analysis. Descriptive
statistics were used for baseline characteristics and out-
comes of interest. No imputation was done for missing
data. Exploratory significance testing was performed be-
tween the three device groups (SC-ICD, DC-ICD, CRT-D),
a two-sided p value of less than 0.05 being required for
significance. The Bonferroni correction was applied for the
post-hoc comparisons. Odds Ratios (OR) with 95% confi-
dence intervals (95% CI) were calculated using univariate
logistic regression methods for identifying predictors of
technical and medical outcomes of interest. SST perform-
ance was assessed by computing sensitivity, specificity, as
well as negative and positive predictive values. Time to first
medical outcomes (hospitalizations, deaths) was described
by Kaplan-Meier curves with Cox regression models ap-
plied for adjustment between study centres and the Hazard
Ratios (HR) with 95% CI were reported. The annual rates
of device therapies and clinical events were presented per
100 patient years together with the Poisson 95% CI. Treat-
ment success was defined as the absence of VTA redetec-
tion following therapy delivery. The power calculation was
based on the results in the ATP arm of the PainFree Rx II
trial [11]. This trial compared the efficacy of ATP for shock
prevention in 313 patients with 4230 spontaneous episodes
during a mean follow-up time of 11months. Using a trans-
lational approach, 200 patients followed during 24months
were deemed necessary to be included in the 4P study. All
analyses were performed with the SAS 9.4 software package
(SAS Institute Inc., Cary, NC, USA) by a senior statistician
expert in the field (L.M.).
Results
Study population
Between September 2011 and January 2014, 199 patients
were enrolled in 10 participating centers in Switzerland.
Three patients were protocol violators and excluded from
the analysis, two of them because of permanent atrial
fibrillation at baseline and one because of participation in
another trial. Thus, 196 patients in three groups (48 SC-
ICD, 50DC-ICD and 98 CRT-D) were included in the
analysis (Fig. 1). Detailed baseline characteristics pre-
sented in Table 1 show that CRT-D patients were older,
more clinically compromised with significantly lower left
ventricular ejection fraction and a significantly higher pro-
portion of patients with symptomatic heart failure in
NYHA II-IV compared to the other 2 groups.
Patients were followed for a mean (± SD) duration of
27.7 (8.6) months, range 0.8 to 44.4months, with similar
durations of follow-up in the three ICD groups (28.1, 27.2,
and 27.7months, respectively). Device programming strat-
egies diverged from recommendations (Figs. 5 and 6 in
Appendix) in all patients but one (Table 4 in Appendix);
in particular, VT cycle length was programmed longer
than recommended in 71.4% of the devices (mean
353 ± 27 and 368 ± 51 ms in primary and secondary pre-
vention, respectively) and the Number of Intervals to
Detect (NID) was programmed shorter than recom-
mended in 47.4%. This phenomenon has been observed
in all participating centers. Programmed mean SVT
limit was consistent with recommendations (256 ± 17
and 259 ± 19 ms in primary and secondary prevention,
respectively). Regarding VF cycle length, there was no
significant difference between primary and secondary
prevention (295 ± 22 and 294 ± 22 ms, respectively) and
no significant difference between SC/DC/CRT-D. In all
patients features of SST were turned “ON” by default.
For further details on programming divergences, refer
to the Table 4 in Appendix.
Device-based management of detected VTAs
During the follow-up period, 5147 episodes were device-
detected, of which 1797 (34.9%) were device-categorized
as possible VTAs (Fig. 2). Of these, 523 were withheld
from therapy delivery by SST (Fig. 2). As shown in
Table 2, the remaining 1274 VTA episodes (1161 VT, 16
FVT, 97 VF) resulted in device therapy delivery: 1208
ATP only, 62 shock only, and 4 ATP followed by a res-
cue shock. The overall device-therapy (ATP ± rescue
shock) delivery rate was 2.8 (95% CI 2.7–3.0) per 100
patient-years (3.3 (3.0–3.7) for SC-ICD, 6.6 (6.2–7.1) for
DC-ICD, and 0.7 (0.6–0.8) for CRT-D). The ATP success
Fig. 1 Patient-flow diagram
Regoli et al. BMC Cardiovascular Disorders          (2019) 19:146 Page 3 of 12
rate was 99.9% (1207 successfully treated episodes of
1208 treated) and the shock success rate was 100% (60
successful shock episodes out of 60 delivered) when
excluding the single patient with an electrical storm (one
non-successful ATP followed by six non-successful
shocks and one successful shock – counted as one
episode). A total of seven inappropriate interventions
occurred in 5 patients (2.6%) due to noise/artefacts (1
ATP, 1 ATP + shock, 2 shocks), non-sustained VT (1
shock), and SVT (2 shocks).
The risk of experiencing one or more VTAs was
higher in patients with a history of VT/VF episodes
(Odds Ratio (OR) 2.9, 95% CI 1.4–6.0, p = 0.004) and in
patients with a secondary prevention indication for ICD
implant (OR 2.4, 95% CI 1.3–4.4, p = 0.006). Patients
treated with a CRT-D were at lower risk of such events
(OR 0.5, 95% CI 0.3–0.9, p = 0.016). Consistently, deliv-
ery of ATP therapy was significantly more likely in pa-
tients with a history of VT/VF (OR 3.5, 95%CI 1.5–8.2,
p = 0.003) or with a secondary prevention indication
Table 1 Baseline characteristics in the 4P-study
SC-ICD (N = 48) DC-ICD (N = 50) CRT-D (N = 98) All patients (N = 196) p value
Patient demographics and clinical presentation
Male (%) 81 88 84 84 0.645
Age (years ± SD) 59 ± 13 63 ± 14 68 ± 11 64 ± 13 0.0012
LVEF (% ± SD) 44 ± 14 42 ± 14 31 ± 10 36 ± 13 < 0.0011,2
QRS (ms ± SD) 107 ± 26 112 ± 30 143 ± 35 126 ± 36 < 0.0011,2
Secondary prevention (%) 58 48 17 35 < 0.0011,2
Device replacement or upgrade (%) 63 41 61 56 0.039
NYHA functional class (%)
I 17 18 10 14 < 0.0011,2
II 19 24 50 34
III 6 8 39 21
IV 2 0 1 1
Underlying cardiac disease (%)
Ischemic heart disease, leading diagnosis 60 66 58 61 0.652
CABG 21 18 30 25 0.239
PCI 27 44 37 36 0.217
Cardiomyopathy, other 25 26 27 26 0.668
Arrhythmia and conduction defects (%)
Non permanent atrial fibrillation 15 24 31 25 0.108
Atrial tachycardia 4 14 10 10 0.251
Ventricular fibrillation 27 12 13 16 0.066
Ventricular tachycardia (sustained) 25 34 8 19 0.0031,2
Ventricular tachycardia (non-sustained) 21 26 16 20 0.372
AV-block 10 10 28 19 0.0082
Medication (%)
Beta-blocker 91 85 90 89 0.333
Calcium channel blocker 18 11 6 10 0.129
Digoxin 0 2 13 7 0.0042
Anti-arrhythmics 25 34 29 29 0.599
of which amiodarone 14 28 25 23 0.187
Implantation type (%)
New 38 59 39 44 < 0.0011,2
Replacement 62 37 33 41
Upgrade 0 4 28 15
Significant post-hoc comparisons are indicated as: 1 SC-ICD vs CRT-D; 2 DC-ICD vs CRT-D
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(OR 3.1, 95%CI 1.4–6.8, p = 0.005), and less likely in
patients treated with a beta-blocker (OR 0.3, 95% CI
0.1–0.7, p = 0.004), with similar findings with regard to
rescue shock delivery.
In total, 146 of 196 patients (74.5%) had one or more
device-detected VTA during the 2.3 years of observation
(Fig. 2). Of these, 44 patients (22.4%) had experienced
one or more VTA episodes per patient that resulted in
therapy delivery by the device: 26 patients (59.1%) with
VT episodes, 6 (13.6%) FVT, and 25 (56.8%) VF (Table 2).
Treatment success rates at the patient level were 100%,
for both ATP and shock therapies.
Adjudicated symptomatic events
During the course of the study, 215 symptomatic clinical
events suggestive of spontaneous VTAs were reported in
45 patients. Using device recordings, 175 episodes (81.4%,
in 39 patients) were adjudicated as appropriate VTA epi-
sodes: 156 VT, 7 FVT, and 12 VF were treated by either
ATP only (125), ATP followed by rescue shock (13), or
shock only (20), and 17 episodes self-terminated before
therapy was delivered. The remaining episodes were
not-classified (29), inappropriate interventions (7; see
above), or short non-sustained ventricular tachycardia
episodes (4).
Mortality
Of the 196 patients included in the analysis, 19 (9.7%)
died during the 2.3 years of observation, 3 in the SC-
ICD group, 4 in the DC-ICD group and 12 in the CRT-
D group, corresponding to annual mortality rates of 2.6,
3.5, and 5.3 per 100 patient-years, respectively (Table 3,
Fig. 3a). Ten patients died of non-cardiac causes, includ-
ing 2 of pneumonia, 2 after suicide, and 1 each of cancer,
end-stage renal disease, stroke, pulmonary embolism,
amyotrophic lateral sclerosis, and one not further speci-
fied. Seven patients (all CRT-D patients) died of cardiac
causes (4 of worsening heart failure, 2 of acute myocardial
Fig. 2 Sequential management of ventricular tachyarrhythmia (VTAs) by ICD devices, from the detection to the electrical therapy of
categorized VTAs
Table 2 Device-based treatment of ventricular tachyarrhythmia
episodes, as number of episodes (number of patients) having
experienced one or more episode
Delivered therapy (%) VT (91.1%) FVT (1.3%) VF (7.6%) Total
ATP only (94.8%) 1146 (23) 11 (4) 51 (11) 1208 (31)
SC-ICD 327 (11) 7 22 356
DC-ICD 739 (4) 2 1 742
CRT-D 80 (8) 2 28 110
ATP + shock (0.3%) 0 (0) 0 (0) 4 (1) 4 (1)
SC-ICD 0 (0) 0 (0) 0 (0) 0 (0)
DC-ICD 0 (0) 0 (0) 0 (0) 0 (0)
CRT-D 0 (0) 0 (0) 4 (1) 4 (1)
Shock only (4.9%) 15 (7) 5 (4) 42 (19) 62 (27)
SC-ICD 6 (3) 0 (0) 8 (5) 14 (8)
DC-ICD 1 (1) 2 (1) 9 (5) 12 (7)
CRT-D 8 (5) 3 (2) 25 (9) 36 (12)
Total 1161 (26) 16 (6) 97 (25) 1274 (44)
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infarctions, and 1 of a not shockable recurrent VF). Two
patients died of unreported causes. No cases of death were
temporally associated with a shock.
Hospitalizations
Overall, 123 hospitalizations of any cause occurred in 72
patients, of which 63 hospitalizations for cardiac reasons
(in 47 patients), 23 hospitalizations for arrhythmia (in 14
patients). As shown in Table 3 and Fig. 3b, hospitalization
rates per 100 patient-years were significantly higher in the
DC-ICD group compared to the SC-ICD group (any
cause, non-cardiac and cardiac causes, and arrhythmia).
Overall mean length of stay was 14.3 ± 40.4 days (a single
patient with long-term hospitalization) with correspond-
ing values of 4.9 ± 4.2, 21.7 ± 68.8, and 12.6 ± 17.1 days for
the SC-ICD, DC-ICD and CRT-D groups, respectively.
The risk of hospitalization was increased in patients with
heart failure NYHA-class III-IV (any hospitalization
with Hazard Ratio (HR) 2.4, 95%CI 1.4–4.1, p = 0.002
and cardiac hospitalizations with HR 2.9, 95%CI 1.4–6.1,
p = 0.004) and in patients taking an anti-arrhythmic drug
(any hospitalization HR 2.1, 95%CI 1.2–3.5, p = 0.006).
Serious adverse device effects (SADE)
Nine SADE (in 6 patients) were reported, including 5
right ventricular lead dysfunctions, 2 device dysfunctions
(1 battery end-of life state and 1 device dislocation), and
2 cases of device pocket infection.
Discussion
The 4P study reports the characteristics of electrical
therapies for ventricular tachyarrhythmic events in a co-
hort of non-selected, non-trial patients with a class I
clinical indication for ICD therapy. Although evidence-
based ICD programming strategies were recommended,
“patient-specific” programming was preferred with SST
features left “ON” in every patient. One or more gener-
ally asymptomatic VTAs were detected in 75% of all in-
cluded patients during 27.7months of observation. Device-
categorized VTAs represented 25% of all device-detected
events; SST discrimination capability was highly accurate
with a PP value of 99.5%. Ninety-five percent of these epi-
sodes were treated by ATP and 5% by a rescue shock with
a therapy success rate of 100% at the patient-level. Overall,
the present study confirms the results of the PainFree SST
study [13] in a real-life clinical setting.
In the present study, device-detected episodes were
frequent (5147 in 146/196, 75% patients during 27.7
months of follow-up). One fourth of these (1274) were
device-categorized as VTAs and electrical therapy was
applied (Fig. 4). Interestingly, although patients were
instructed to seek for medical advice in the case of
symptoms suggesting underlying arrhythmia, only 45
patients reported 215 such events of which 81% were
adjudicated as VTAs. This might suggest that most
arrhythmic events and ATP therapies remain asymp-
tomatic. In the recently published results of the Span-
ish UMBRELLA registry, in which devices preceding
SST generation devices were also included, only 5951
VTAs were detected in 605 of 1514 included (40%)
patients during 26 months of follow-up with 3353
(56%) categorized as VTAs (56%) [12].
Overall in 4P, 95% of all device-categorized VTAs were
effectively treated with ATP and only 5% required a res-
cue shock. Antitachycardia pacing and shocks restored
sinus rhythm in 99.9 and 100.0% of the episodes, re-
spectively. In the UMBRELLA registry, approximately
80% of the VTA episodes were treated with ATP and
20% required a rescue shock [12]. The shock rate in 4P
(15 per 100 patient-years) was similar to that published
in PainFree SST (16 per 100 patient-years) [13] and in
ADVANCE-III (19 and 30 per 100 patient-years in the
NID 30/40 and 18/24 treatment groups, respectively)
[16]. The ATP rate in 4P was higher than in the two
former trials which can at least partially be explained by
a shorter than recommended NID in almost 50% of the
patients. The latter may have contributed to an in-
creased number of ATP-treatments, consistent with the
findings in the ADVANCE-III [16, 17] and PainFree SST
[13] trials. Another reason accounting for the high rate
Table 3 Death and Hospitalization rates per 100 patient-years (95%CI) by cause and device type
SC-ICD DC-ICD CRT-D Overall
Death 2.6 (0.8–8.3) 3.5 (1.3–9.4) 5.3 (3.0–9.4) 4.2 (2.6–6.6)
Any hospitalization 16.0 (10.1–25.4) 36.1* (26.6–49.1) 28.3 (22.2–36.2) 27.2 (22.8–32.5)
Non-cardiac hospitalization 7.1 (3.6–14.2) 17.6 † (11.4–27.3) 14.2 †† (10.0–20.0) 13.3 (10.3–17.1)
Cardiac hospitalization 8.9 (4.8–16.5) 18.5 ** (12.1–28.4) 14.2 (10.0–20.0) 13.9 (10.9–17.8)
Hospitalization for arrhythmia 1.8 (0.4–7.1) 7.0 # (3.5–14.1) 5.8 ## (3.3–9.9) 5.1 (3.4–7.7)
Ventricular pacing % 6.9 (0–29.2) 11.3 (0–41.1) 96.8 (92.8–100.0) /
Mean values with corresponding standard deviation between parenthesis
* p = 0.010 vs. SC-ICD
† p = 0.03 vs. SC-ICD; †† p = 0.045 vs. SC-ICD
** p = 0.04 vs. SC-ICD
# p = 0.017 vs. SC-ICD; ## p = 0.043 vs. SC-ICD
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of ATP therapies is related to the large proportion of pa-
tients who presented a secondary prevention ICD indi-
cation and underwent device replacement.
Worthy of note, despite evidence-based programming
recommendations [13, 14, 16], in 4P patient-specific
settings were usually preferred and only one ICD was
programmed in full compliance with the handed-out
recommendations (Figs. 5 and 6 in Appendix). In spite of
this, the inappropriate shock rate in 4P (2.6% of the pa-
tients during 27.7months of follow-up) was lower
Fig. 3 Kaplan-Meier curves for survival (a) and freedom of hospitalization (b)
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compared to the UMBRELLA registry (5% during 25
months) [12] and the PainFree SST trial (2.8 and 3.7%
during 22months for patients with dual/triple-chamber
and single chamber ICDs, respectively) [13]. Moreover,
the incidence of inappropriate shocks was much lower
than in the pivotal RCTs (10 to 24% of the patients during
20 to 45months) [18].
While fully acknowledging that individual ICD pro-
gramming may be required in specific clinical situa-
tions, it appears unlikely that virtually all patients
included in 4P had characteristics diverging from
those of the validation trials. The EMPIRIC trial
clearly showed that standardized empiric ICD pro-
gramming for VT/VF settings was at least as effective
as patient-specific programming [3]. Whether similar
findings might still be expected with last generation
ICDs could obviously not be explored in the context
of the 4P study.
Cardiovascular hospitalization rates were low in 4P,
representing approximately 50% of the rates pub-
lished in the ADVANCE III trial [19]. However, in
4P (Table 3 and Fig. 3b), patients implanted with a
DC-ICD experienced significantly more hospitaliza-
tions (for any cause, for cardiac causes and for
arrhythmic causes) and had more VTAs requiring
electrical therapy than patients implanted with a SC-
ICD. Compared to patients implanted with SC-ICD,
DC-ICD patients in 4P were generally older, sicker
at baseline, and presented a higher incidence of
negative prognostic factors (including cardiovascular
disease and arrhythmia history), precluding direct
comparison between groups and indirect comparison
with other studies.
Study limitations
The present study has some limitations. First, ICD pa-
tients with heart failure disease and left ventricular
dysfunction often present with co-existing comorbidi-
ties such as diabetes mellitus, metabolic syndrome,
and moderate-to-severe renal impairment. These con-
ditions and their therapeutic control over time may
have had an important impact on hospitalization rates,
mortality rates, as well as ventricular arrhythmic bur-
den [20–23]. Furthermore, the identification of pa-
tients at higher risk by integrating echocardiographic
evaluations of cardiac function and left ventricular
dimensions with neuroendocrinal and inflammatory
parameters could certainly have been relevant. How-
ever, neither detailed echocardiographic evaluation
nor sampling of particular hematologic markers, were
defined by the study protocol. Second, patients with
persistent atrial fibrillation were not included. This
may have contributed to the low rate of inappropriate
shocks. However, 25% of the included patients had a
history of non-persistent atrial fibrillation. Third, the
comparisons between the different ICD models should
be considered exploratory as the study was not de-
signed for this purpose. On the other hand, in a con-
text of widely available strong evidence of the benefits
and risks of ICD therapy, 4P offers unique real-world
insights into the patient profiles, arrhythmic events
and electrical therapies as they occur in daily routine
and confirms that results achieved in clinical outcome
trials are reproducible in conditions of daily practice.
Fourth, patients included in 4P were followed during
only 2 years with 44% of them receiving a new im-
plant. Long term studies over 11 years which included
patients who underwent multiple ICD device replace-
ments suggest that the proportion of patients experi-
encing appropriate and inappropriate shocks may
increase over time [24]. Thus, the low rates of appro-
priate and inappropriate shocks observed in 4P may
be explained, at least in part, by the comparatively
short duration of observation.
Conclusion
In conclusion, in a daily practice setting of ICD pa-
tients with a class I indication for an ICD, device-
detected, −categorized and –treated episodes were
frequent. Almost one patient out of every four experi-
enced one or more potentially lethal ventricular tachy-
arrhythmia in the course of a two-year follow-up and
benefitted from life-saving electrical therapy, mostly
through effective ATP delivery. Overall, the present
real-life results confirm the robustness SST for the de-
tection, categorization, and treatment of ventricular
arrhythmias to limit the overall incidence of ICD
shocks. More studies would be desirable to confirm
the effect of SST on the long-term technical and medical
outcomes of ICD patients.
Fig. 4 Last generation ICDs are primarily ATP devices with
defibrillation backup (rescue shock)
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Primary prevention (pts) 121 19 25 77
FVT detection- ON [n, (%)] 19 (10.2) 1 (2.3) 4 (8.3) 14 (15.1%)
VT detection- ON [n, (%)] 90 (74.4) 15 (78.9) 18 (72.0) 57 (64.0)
PR Logic/ Wavelet- OFF or Monitor [n, (%)] 18 (14.9) 3 (15.8) 2 (8.0) 13 (16.9)
Onset ON or OFF [n, (%)] 49 (40.5) 12 (53.1) 9 (36.0) 28 (36.4)
T-Wave- OFF [n, (%)] 6 (5) 3 (15.8) 0 3 (3.9)
RV-Lead Noise [n, (%)] 3 (2.5) 2 (10.5) 0 1 (1.3)
ATP before charging 8 (6.6) 1 (5.3) 2 (8.0) 5 (6.5)
FVT- ATP & shocks 121 (100) 19 (100) 25 (100) 77 (100)
VT- ATP & shocks 121 (100) 19 (100) 25 (100) 77 (100)
Secondary prevention (pts) 64 25 23 16
FVT detection- ON [n, (%)] 19 (29.7) 8 (32.0) 9 (39.1) 2 (12.6)
VT detection- OFF [n, (%)] 11 (17.2) 6 (24.0) 5 (21.7) 0
PR Logic/ Wavelet- OFF or Monitor [n, (%)] 4 (6.3) 3 (12.0) 0 1 (6.3)
Onset ON or OFF [n, (%)] 32 (50.0) 10 (40.0) 14 (60.8) 8 (50.0)
ATP before charging 8 (12.5) 3 (12.0) 2 (8.7) 3 (18.8)
FVT- ATP & shocks 121 (100) 19 (100) 25 (100) 77 (100)
Table 5 Classification of 176 symptomatic VTA episodes in 39 patients
VT (n = 22) FVT (n = 10) VF (n = 7) Total
ATP 125 0 0 125
ATP and shock 11 1 1 13
Shock only 11 1 9 21
Self-terminating 10 5 2 17
Total episodes 157 7 12 176
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Fig. 6 Specific programming information handed out to implanters before trial initiation (secondary prevention)
Fig. 5 Specific programming information handed out to implanters before trial initiation (primary prevention)
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